These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 16203138)

  • 1. Estrogen receptor ligands. Part 14: application of novel antagonist side chains to existing platforms.
    Blizzard TA; Morgan JD; Chan W; Birzin ET; Pai LY; Hayes EC; DaSilva CA; Mosley RT; Yang YT; Rohrer SP; Dininno F; Hammond ML
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5124-8. PubMed ID: 16203138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estrogen receptor ligands. Part 9: Dihydrobenzoxathiin SERAMs with alkyl substituted pyrrolidine side chains and linkers.
    Blizzard TA; Dininno F; Morgan JD; Chen HY; Wu JY; Kim S; Chan W; Birzin ET; Yang YT; Pai LY; Fitzgerald PM; Sharma N; Li Y; Zhang Z; Hayes EC; Dasilva CA; Tang W; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2005 Jan; 15(1):107-13. PubMed ID: 15582421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain.
    Blizzard TA; DiNinno F; Chen HY; Kim S; Wu JY; Chan W; Birzin ET; Yang YT; Pai LY; Hayes EC; DaSilva CA; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3912-6. PubMed ID: 15993065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators.
    Kim S; Wu JY; Birzin ET; Frisch K; Chan W; Pai LY; Yang YT; Mosley RT; Fitzgerald PM; Sharma N; Dahllund J; Thorsell AG; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    J Med Chem; 2004 Apr; 47(9):2171-5. PubMed ID: 15084115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estrogen receptor ligands. 12. Synthesis of the major metabolites of an ERalpha-selective, dihydrobenzoxathiin antagonist for osteoporosis.
    Kim S; Wu JY; Zhang Z; Tang W; Doss GA; Dean BJ; Dininno F; Hammond ML
    Org Lett; 2005 Feb; 7(3):411-4. PubMed ID: 15673252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estrogen receptor ligands. Part 8: Dihydrobenzoxathiin SERAMs with heteroatom-substituted side chains.
    Blizzard TA; DiNinno F; Morgan JD; Wu JY; Chen HY; Kim S; Chan W; Birzin ET; Yang YT; Pai LY; Zhang Z; Hayes EC; DaSilva CA; Tang W; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3865-8. PubMed ID: 15225686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of the diastereomerism of dihydrobenzoxathiin SERMs for ER alpha by molecular modeling.
    Zhuang S; Zhang J; Zhang F; Zhang Z; Wen Y; Liu W
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7298-305. PubMed ID: 22061644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New scaffolds for the design of selective estrogen receptor modulators.
    Martín-Santamaría S; Rodríguez JJ; de Pascual-Teresa S; Gordon S; Bengtsson M; Garrido-Laguna I; Rubio-Viqueira B; López-Casas PP; Hidalgo M; de Pascual-Teresa B; Ramos A
    Org Biomol Chem; 2008 Oct; 6(19):3486-96. PubMed ID: 19082149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen receptor ligands. Part 5: The SAR of dihydrobenzoxathiins containing modified basic side chains.
    Tan Q; Birzin ET; Chan W; Tien Yang Y; Pai LY; Hayes EC; DaSilva CA; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Jul; 14(14):3747-51. PubMed ID: 15203155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzothiophenes containing a piperazine side chain as selective ligands for the estrogen receptor alpha and their bioactivities in vivo.
    Yang C; Xu G; Li J; Wu X; Liu B; Yan X; Wang M; Xie Y
    Bioorg Med Chem Lett; 2005 Mar; 15(5):1505-7. PubMed ID: 15713417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats.
    Hummel CW; Geiser AG; Bryant HU; Cohen IR; Dally RD; Fong KC; Frank SA; Hinklin R; Jones SA; Lewis G; McCann DJ; Rudmann DG; Shepherd TA; Tian H; Wallace OB; Wang M; Wang Y; Dodge JA
    J Med Chem; 2005 Nov; 48(22):6772-5. PubMed ID: 16250633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor ligands. Part 4: The SAR of the syn-dihydrobenzoxathiin SERAMs.
    Kim S; Wu J; Chen HY; Birzin ET; Chan W; Yang YT; Colwell L; Li S; Dahllund J; DiNinno F; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Jun; 14(11):2741-5. PubMed ID: 15125925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
    Jain N; Xu J; Kanojia RM; Du F; Jian-Zhong G; Pacia E; Lai MT; Musto A; Allan G; Reuman M; Li X; Hahn D; Cousineau M; Peng S; Ritchie D; Russell R; Lundeen S; Sui Z
    J Med Chem; 2009 Dec; 52(23):7544-69. PubMed ID: 19366247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benzothiophene and naphthalene derived constrained SERMs.
    Wallace OB; Bryant HU; Shetler PK; Adrian MD; Geiser AG
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5103-6. PubMed ID: 15380208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor ligands. Part 7: Dihydrobenzoxathiin SERAMs with bicyclic amine side chains.
    Blizzard TA; DiNinno F; Morgan JD; Chen HY; Wu JY; Gude C; Kim S; Chan W; Birzin ET; Tien Yang Y; Pai LY; Zhang Z; Hayes EC; DaSilva CA; Tang W; Rohrer SP; Schaeffer JM; Hammond ML
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3861-4. PubMed ID: 15225685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estrogen receptor beta selective ligands: discovery and SAR of novel heterocyclic ligands.
    Chesworth R; Wessel MD; Heyden L; Mangano FM; Zawistoski M; Gegnas L; Galluzzo D; Lefker B; Cameron KO; Tickner J; Lu B; Castleberry TA; Petersen DN; Brault A; Perry P; Ng O; Owen TA; Pan L; Ke HZ; Brown TA; Thompson DD; DaSilva-Jardine P
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5562-6. PubMed ID: 16219463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benzopyrans are selective estrogen receptor beta agonists with novel activity in models of benign prostatic hyperplasia.
    Norman BH; Dodge JA; Richardson TI; Borromeo PS; Lugar CW; Jones SA; Chen K; Wang Y; Durst GL; Barr RJ; Montrose-Rafizadeh C; Osborne HE; Amos RM; Guo S; Boodhoo A; Krishnan V
    J Med Chem; 2006 Oct; 49(21):6155-7. PubMed ID: 17034120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A selective estrogen receptor modulator for the treatment of hot flushes.
    Wallace OB; Lauwers KS; Dodge JA; May SA; Calvin JR; Hinklin R; Bryant HU; Shetler PK; Adrian MD; Geiser AG; Sato M; Burris TP
    J Med Chem; 2006 Feb; 49(3):843-6. PubMed ID: 16451049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in estrogen receptor modulators.
    Henke BR; Heyer D
    Curr Opin Drug Discov Devel; 2005 Jul; 8(4):437-48. PubMed ID: 16022180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.